The myelodysplastic/myeloproliferative disorders: the interface.
Most patients with myelodysplastic syndromes can be identified easily and separated from patients who have myeloproliferative disorders. A few have overlapping features, however, with evidence of morphologic dysplasia and a proliferative advantage of one or more of the myeloid differentiating cell lines. For practical purposes and therapeutic considerations, chronic myelomonocytic leukemia is viewed now as a composite disorder along with atypical chronic myeloid leukemia and juvenile myelomonocytic leukemia.
Bennett
John M
JM
Department of Medicine, Pathology, and Laboratory Medicine, University of Rochester Medical Center, The James P. Wilmot Cancer Center, 601 Elmwood Avenue, Box 704, Rochester, NY 14642, USA. John_Bennett@urmc.rochester.edu
D011905:Genes, ras; D006801:Humans; D007951:Leukemia, Myeloid / Q000235:genetics / Q000473:pathology; D015477:Leukemia, Myelomonocytic, Chronic / Q000235:genetics / Q000473:pathology / Q000628:therapy; D009190:Myelodysplastic Syndromes / Q000235:genetics / Q000473:pathology* / Q000628:therapy; D009196:Myeloproliferative Disorders / Q000235:genetics / Q000473:pathology* / Q000628:therapy